Skip to content
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Monebo's Kinetic Software Library provides ectopic beat detection, QRS feature extraction, and heart rate and rhythm analysis for ECG devices. For ECG device engineering and regulatory teams, rhythm analysis could become a choice between building it and licensing it.

  • 01Fifty-one later FDA clearances trace their predicate lineage to Monebo's earlier libraries, a track record anyone evaluating the new one can check.

Nov 1, 2026

AI Takes Center Stage at AHA 2026. Experts Warn It Must Be Built for Everyone

AI Takes Center Stage at AHA 2026. Experts Warn It Must Be Built for Everyone

AI-enabled ECG, echocardiography and imaging studies are a major theme at the American Heart Association's Scientific Sessions 2026 in Chicago, November 6 to 9. A Frontiers in Cardiovascular Medicine policy brief led by Emory cardiologist Dr. Jose R. Medina-Inojosa argues precision cardiology must be designed with equity from inception. He says the biggest factor is not algorithm accuracy but the pathway from result to clinical action.

  • 01AHA 2026 late-breakers on AI include WATCH-LV, AI ECHO INSIGHT, PROVAR+ and LIFE-AI, all presented Monday, November 9.
  • 02Medina-Inojosa says equity from inception means training and validating on representative data and reporting subgroup performance before deployment.
  • 03Programs in Nigeria and Uganda show AI-ECG and AI-guided echo can extend cardiac care where specialists are scarce.

Nov 1, 2026

Medicus report projects 24% more surgery center cases and 2027 anesthesiology, GI shortages

Medicus report projects 24% more surgery center cases and 2027 anesthesiology, GI shortages

Ambulatory surgery center volumes are projected to rise 24% over the next decade, with anesthesiology and gastroenterology shortages projected for 2027. That puts potential staffing constraints early in the growth period, so operators planning coverage may find the nearer 2027 date sets the pace.

  • 01A 24% ten-year forecast and a 9% forecast for 2023 to 2028 measure different windows; check the time frame and start year before putting either in a budget.
  • 02With about nine in ten ASCs at least partly physician-owned, a staffing gap could hit physician owners directly as clinicians and investors.

Oct 30, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512